从回购护盘到高位减持，翔宇医疗脑机接口狂欢下重要股东减持引投资者质疑

Core Viewpoint - The surge in Xiangyu Medical's stock price is driven by the excitement surrounding the "brain-computer interface" concept, despite concerns over a major shareholder's plan to reduce their stake and the company's declining net profits [1][2][3]. Group 1: Stock Performance - Xiangyu Medical's stock price increased significantly at the beginning of 2026, with a maximum rise of 57% over three trading days, reaching a high of 95 yuan, marking a cumulative increase of over 300% from its low in 2024 [1][2]. - The stock's performance triggered an abnormal trading situation, with the stock price deviating by 30% over three consecutive trading days [3]. Group 2: Shareholder Actions - On January 13, 2026, Xiangyu Medical announced that its major shareholder, Anyang Qixu Trade Consulting Service Center, planned to reduce its stake by no more than 3% between February 4 and May 3, 2026 [1]. - The reduction plan raised questions among investors, especially given the recent stock price surge [4]. Group 3: Company Outlook and Strategy - Xiangyu Medical remains optimistic about its future, focusing on non-invasive brain-computer interface technology and planning to launch several new products in 2026, aiming to expand its presence in over 1,000 top-tier hospitals [2][4]. - The company has invested significantly in research and development, with R&D expenses increasing by 42% in 2024 and 20.19% in the first three quarters of 2025 [6]. Group 4: Financial Performance - Despite the stock price increase, Xiangyu Medical's net profit has been declining, with a 54.68% drop in 2024 and a 40.09% decrease in the first three quarters of 2025 [5][6]. - The company attributes the decline in net profit to increased R&D investments and challenges in the economic environment affecting revenue [6].